Tom Wilemon

Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).

Study identifies biomarker for breast cancer response to immunotherapy

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Clinical trial to test immunotherapy for rectal cancer

A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.

Ciombor chosen for NCI clinical investigator team leadership award

Kristen Ciombor, MD, MSCI, is one of 10 physicians nationwide selected by the National Cancer Institute (NCI) for the 2021 Cancer Clinical Investigator Team Leadership Award.

Davis promoted to Vice President for VUMC Cancer Care Network and Strategy

Nancy Davis, MD, has been promoted to Vice President for Cancer Care Network and Strategy at Vanderbilt University Medical Center, a new position responsible for developing provider relationships with other health care systems and expanding access to oncology care throughout Tennessee and other states.

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

1 15 16 17 18 19 39